Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Nuvastatic

Phase 3Small molecule

NNatureceuticals Sdn Bhd

1

Indications

6

Total Trials

3

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Fatigue

NCT07669454

Q1 2027

Phase 3Recruiting

Fatigue

NCT07669519

Clinical

Trials by Indication[1]

Fatigue3 trials

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300 mg Capsules in Reducing Chemotherapy-Induced Fatigue in Patients With Metastatic Triple-Negative Breast Cancer Receiving Standard Chemotherapy

Recruiting·NNatureceuticals Sdn Bhd·Phase 3·NCT07669467·250 enrolled

Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy

Recruiting·NNatureceuticals Sdn Bhd·Phase 3·NCT07669519·180 enrolled

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.

Recruiting·NNatureceuticals Sdn Bhd·Phase 3·NCT07669454·250 enrolled

COVID-191 trial

To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.

Unknown status·NNatureceuticals Sdn Bhd·Phase 1·NCT04542447·10 enrolled

Diabetic Retinopathy1 trial

Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.

Completed·NNatureceuticals Sdn Bhd·Phase 1/2·NCT04552600·100 enrolled

Breast Neoplasms1 trial

Phase III Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Breast Cancer Patients Undergoing Chemotherapy

Completed·NNatureceuticals Sdn Bhd·Phase 3·NCT07669506·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Nuvastatic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nuvastatic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nuvastatic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Natureceuticals Sdn Bhd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNatureceuticals Sdn Bhd

Related News